NCT05930145 Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke
| NCT ID | NCT05930145 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundación EPIC |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-03-14 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-03-14 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Several studies have demonstrated that simultaneous treatment with two stentrievers (STs) as rescue treatment is very effective, with high recanalization rates even in this group of patients where other revascularization techniques have failed. There has been no observed increase in hemorrhagic complications. Recently, a prospective study has been published where treatment with two ST has been shown to be effective and safe if used as a first-choice treatment (not as rescue) with a successful recanalization rate (eTICI 2c/3) after the first pass of 69%. These results have been reinforced after the publication of a randomized study that confirms, in vitro, the superiority of using two ST over one.
Eligibility Criteria
Inclusion Criteria: * A new disabling focal neurological deficit compatible with acute cerebral ischemia. * Any age. Informed consent obtained from the patient or representative. * NIHSS score ≥ 6. * Pre-existing functional clinical status less than or equal to 2 according to the mRS clinical scale. * Maximum time of 24 hours from symptom onset to arterial puncture. • TICI 0-1 in the diagnosed TICA (terminal internal carotid artery) , MCA (middle cerebral artery), and BA( basilar artery confirmed by angioCT and angiography). * ASPECTs score on baseline CT greater than or equal to 6. * In cases where it is indicated, prior intravenous fibrinolysis will be administered according to the protocols of each center. Exclusion Criteria: * Those described in the usual protocols for mechanical thrombectomy of each hospital. * Pre-existing functional clinical status greater than 2 according to the mRS clinical scale * Patients with tandem lesions of dissection or arteriosclerotic origin located in the extracranial internal carotid artery. * Initiation of treatment with a different technique than the one described. * Inability to use a proximal balloon guide catheter. * Use of aspiration catheter. * Intracranial atherosclerotic plaque as the cause of occlusion. * Advanced or terminal disease with a life expectancy of less than 6 months. * Patient who is participating in another study that may affect this one. * ASPECTS score less than or equal to 6 on baseline CT. * Evidence of significant hemorrhage or mass effect with midline shift on baseline CT. * Patients with occlusions in multiple vascular territories. * Evidence of intracranial tumor (except for small meningiomas)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05930145 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05930145 currently recruiting?
Yes, NCT05930145 is actively recruiting participants. Contact the research team at peveval@yahoo.es for enrollment information.
Where is the NCT05930145 trial being conducted?
This trial is being conducted at Essen, Germany, Barakaldo, Spain, Oviedo, Spain, Valladolid, Spain.
Who is sponsoring the NCT05930145 clinical trial?
NCT05930145 is sponsored by Fundación EPIC. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.